Vaccine Contract Manufacturing Market Size, Share & Trends Analysis Report By Scale of Operation (Commercial, Clinical, Preclinical), By Vaccine Type (Sub-attenuated Vaccines, Live-attenuated Vaccines, Inactivated Vaccines, Others), By Service (Fill/Finish, Analytical and QC Studies, Cell/Virus Banking, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Vaccine Contract Manufacturing Market Size

The global vaccine contract manufacturing market size was valued at USD 3.49 billion in 2025 and is projected to grow from USD 3.92 billion in 2026 to USD 10.03 billion by 2034, registering a CAGR of 12.45% during the forecast period from 2026 to 2034. North America dominated the vaccine contract manufacturing market with a market share of 38.4% in 2025.

Vaccines play a major role in the prevention and eradication of several life-threatening infectious diseases across the world. The rise in the demand for treating such diseases, along with R&D related to new vaccine discovery and a surge in vaccination awareness among people, are the major factors boosting the vaccine contract manufacturing market growth. Vaccines include several varieties such as live-attenuated, inactivated, sub-unit, recombinant, toxoid, and many others.

This market includes various outsourcing services, including development, analytical, upstream and downstream processing, quality control, supply chain, etc. Contract manufacturing of vaccines is provided at commercial, clinical, and preclinical scales. Biopharmaceutical companies continuously outsource their vaccines to meet the clinical demand during epidemics and pandemics.

Scale of Operation Insights

The clinical segment dominates the global market and is projected to exhibit a CAGR of 13.28% over the forecast period. Vaccines must be produced in large batches during the clinical phase and at a lower cost per dose for broad and effective production. Production of sufficient doses of vaccines safely and with efficacy is becoming a challenge. Vaccine production involves tightly controlled conditions that are difficult to maintain during the scale-up from a research lab to global production. Moreover, there is added time pressure to scale vaccine production faster. Contract manufacturers partnered with bioprocessing companies to provide required vaccine doses in various clinical trial phases.

Request Customizationto receive a tailored report.

Vaccine Type Insights

The sub-attenuated vaccine segment is the largest revenue contributor to the market and is expected to exhibit a CAGR of 11.76% throughout the forecast period. Sub-unit vaccines have been developed for a number of diseases, such as hepatitis, influenza, pertussis, pneumococcal disease, meningococcal disease, and human papillomavirus (HPV). National and international organizations have mandated the vaccination program to enable more people to get vaccinated in response to rising infectious illnesses causing epidemics and pandemics due to declining immunization coverage in many places. The anticipated surge in vaccine production will likely benefit CMOs' expertise in vaccine manufacturing services.

Service Insights

The fill/finish segment owns the largest market share and is expected to exhibit a CAGR of 12.78% throughout the forecast period. Fill or finish services are the most critical and specialized aspect of manufacturing biologicals. It is typically the last step of the injectable drug manufacturing process. Fill or finish providers can offer specialized services in areas such as types of primary packaging containers (ampoules, cartridges, syringes, and vials), various biologics, and scale of operations (preclinical, clinical, and commercial). Their services include formulation, fill, packaging and labeling, lyophilization, and other services for the final production of the drug product. Fill/finish services are frequently expensive in manufacturing and are subject to strict regulation by regulatory bodies. Vaccine producers working to overcome these obstacles rely on CMOs to outsource their goods quickly and affordably.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global vaccine contract manufacturing market shareholder and is anticipated to exhibit a CAGR of 12.81% during the forecast period. The US is the major revenue contributor in North America mainly due to an increase in the demand for vaccines, reflecting the growth in awareness of vaccinations and their benefits against infectious diseases. This led to the development of regular vaccination programs and new immunizations. Moreover, North America has widespread vaccine manufacturers and an increasing number of biopharmaceutical companies. All these factors collectively elevated the growth of North America in the vaccine contract manufacturing market.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Vaccine Contract Manufacturing Market Trends

Europe is estimated to exhibit a CAGR of 12.77% over the forecast period. The increase in vaccine contract manufacturing in Europe can be attributed to several significant causes, such as the aging population, the prevalence of bacterial and viral diseases, the growing need for immunizations, and the rapid expansion of the biopharma and biotech sectors. The vaccine outsourcing sector is being driven by increased investments resulting from the strong emphasis of government entities on research and development (R&D) in various European areas.

Asia-Pacific is expected to grow rapidly in the vaccine contract manufacturing market throughout the forecast period. This is mainly due to the involvement of contract manufacturers in the development of vaccines, which is growing at a constant pace. The region is expected to emerge as the fastest-growing region for developing and manufacturing vaccines. The top revenue-generating countries in this region are China, India, Japan, South Korea, and Australia. India is expected to have the most significant growth because of the need for immunizations to control the spread of contagious illnesses, such as hepatitis B, tuberculosis, Haemophilus influenzae type B, and other ailments.

In Latin America, economic globalization has increased the movement of people and goods with changes in occupational health and environmental hazards constantly transferring health risks.

• For instance, an epidemiologic transition with a gradual increase in the rate of infectious diseases is observed. The dominant diseases in Latin America are expected to exceed the US and other developed countries in the next 25 years. The potential for the spread of newly-discovered or re-emerging infectious diseases.

List of Key and Emerging Players in Vaccine Contract Manufacturing Market